# Phase III Study of OT202 in Treating Moderate to Severe Dry Eye

> **NCT07740564** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Ocumension Therapeutics (Suzhou) Co., Ltd** · enrollment: 842 (estimated)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** OT202 conc 1%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07740564
- **Lead sponsor:** Ocumension Therapeutics (Suzhou) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2029-01
- **Final completion:** 2029-05
- **Target enrollment:** 842 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07740564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07740564, "Phase III Study of OT202 in Treating Moderate to Severe Dry Eye". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07740564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*